- Home
- SA vs NEO Comparison
SA vs NEO Comparison
Compare SA & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- NEO
- Stock Information
- Founded
- SA 1979
- NEO 2001
- Country
- SA Canada
- NEO United States
- Employees
- SA N/A
- NEO N/A
- Industry
- SA Precious Metals
- NEO Precision Instruments
- Sector
- SA Basic Materials
- NEO Health Care
- Exchange
- SA Nasdaq
- NEO Nasdaq
- Market Cap
- SA 1.0B
- NEO 1.2B
- IPO Year
- SA N/A
- NEO 1999
- Fundamental
- Price
- SA $11.68
- NEO $9.49
- Analyst Decision
- SA
- NEO Strong Buy
- Analyst Count
- SA 0
- NEO 10
- Target Price
- SA N/A
- NEO $19.78
- AVG Volume (30 Days)
- SA 654.3K
- NEO 1.5M
- Earning Date
- SA 05-12-2025
- NEO 04-29-2025
- Dividend Yield
- SA N/A
- NEO N/A
- EPS Growth
- SA N/A
- NEO N/A
- EPS
- SA N/A
- NEO N/A
- Revenue
- SA N/A
- NEO $660,566,000.00
- Revenue This Year
- SA N/A
- NEO $12.89
- Revenue Next Year
- SA N/A
- NEO $11.36
- P/E Ratio
- SA N/A
- NEO N/A
- Revenue Growth
- SA N/A
- NEO 11.65
- 52 Week Low
- SA $10.14
- NEO $8.98
- 52 Week High
- SA $20.55
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- SA 49.31
- NEO 40.10
- Support Level
- SA $11.62
- NEO $9.57
- Resistance Level
- SA $12.54
- NEO $10.37
- Average True Range (ATR)
- SA 0.49
- NEO 0.56
- MACD
- SA 0.04
- NEO 0.12
- Stochastic Oscillator
- SA 50.29
- NEO 25.39
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.